HMPL 004

Drug Profile

HMPL 004

Alternative Names: HMPL-004

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Developer Hutchison MediPharma; Nutrition Science Partners
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Discontinued Ulcerative colitis

Most Recent Events

  • 02 Aug 2016 Hutchinson MediPharma announces intention to submit IND application to FDA in 2017
  • 27 Jul 2015 Development is active in USA; Hutchison Medipharma and Nestle Health Science are discussing next steps for development of HMPL 004
  • 17 Jul 2013 Hutchison Medipharma and Nutrition Science Partners initiate enrolment in a phase III NATRUL-4 trial for Ulcerative colitis (treatment-resistant) in the USA (NCT01882764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top